Clinical Trials Logo

Clinical Trial Summary

This clinical research study investigates IMA201 which is composed of special immune cells (T cells, also called T lymphocytes) being genetically modified by introduction of a tumor-antigen specific T cell receptor (TCR) to fight against cancer. Patients that choose to take part in this study have advanced cancer where there is no (further) standard treatment for their cancer available OR current treatments are not tolerated.

The main purpose of this clinical research study is to confirm the safety of IMA201 and to define the highest safe dose of IMA201 cells to give to patients. The study will also investigate what the specific side effects of this treatment are, and to see whether this therapy shows clinical activity in patients with their advanced cancer.


Clinical Trial Description

SCREENING: First, the patient will have 2 sets of screening tests to determine eligibility: HLA (human leukocyte antigen) screening and Main screening. After both screenings are completed and if the patient is eligible, blood will be taken for the manufacture of IMA201.

The HLA screening test will be done by an investigational device. Patients must have the HLA-A*02:01 subtype to continue to the Main screening of the study. The Main screening will include medical tests and exams, including a tumor biopsy that will be tested for specific biomarkers by an investigational device called IMA201_Detect. Patients must be positive for at least one of the study's biomarkers to continue onto the leukapheresis part of the study.

Manufacturing phase: From the patient's blood collected at the leukapheresis, the investigators will make the IMA201 TCR-engineered T cells. In order to insert the new gene into the patient's T-cells, investigators will use a gene transfer technology. This will be done with a lentiviral vector derived from a virus. The vector was made specifically for this study and will carry the TCR genes into the T cells.

TREATMENT: In other clinical studies using T cells, some investigators found that giving chemotherapy before the T cell infusion can improve the amount of time the T cells stay in the body. Giving chemotherapy before a T cell infusion is called lymphodepletion. The chemotherapy used for lymphodepletion in this study will be a combination of cyclophosphamide and fludarabine which would be given in the days before the IMA201 T cell infusion. Two days after the last chemotherapy dose, the patient will be admitted to the hospital the night before the IMA201 infusion. The IMA201 treatment will be given at MD Anderson Cancer Center.

After IMA201 infusion, a low dose of IL-2 will be given twice daily for a period of time.

Since this study involves gene therapy, patients will be monitored throughout the study and for up to a total of 15 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03247309
Study type Interventional
Source Immatics US, Inc.
Contact Hong Ma, M.D.
Phone 346-204-5350
Email ma@immatics.com
Status Recruiting
Phase Phase 1
Start date September 26, 2017
Completion date December 31, 2033

See also
  Status Clinical Trial Phase
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Active, not recruiting NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Completed NCT01077414 - Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness
Enrolling by invitation NCT02565004 - Clinical and Laboratory Analysis of Familial Cancer N/A
Completed NCT01340846 - A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors Phase 1
Active, not recruiting NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center N/A
Completed NCT03272880 - Utilizing the Arts to Improve Health, Resilience, and Well-Being Among Cancer Patients and Their Caregivers N/A
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer N/A
Active, not recruiting NCT03548077 - POWERPLAY: Promoting Men's Health at Work N/A
Completed NCT03503838 - A Pilot Study of Online Yoga for MPN Patients N/A
Active, not recruiting NCT00984035 - Investigation of Cisplatin-Related Kidney Toxicity N/A
Completed NCT01447186 - Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men N/A
Not yet recruiting NCT03257969 - Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients With Risk Factors N/A
Recruiting NCT02883699 - Individually Tailored Training Prescriptions in Cancer Patients: The TOP Study N/A
Recruiting NCT02869802 - Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis N/A
Active, not recruiting NCT02891993 - Pilot Study of a Symptom Monitoring Intervention for Hospitalized Patients With Cancer N/A